Panacea in stock spiral as WHO disqualifies three vaccines
This article was originally published in Scrip
Executive Summary
Shares of Panacea Biotec, India's third-largest biotech firm by revenue, continued to feel the heat on Indian bourses after the World Health Organisation (WHO) delisted three of the firm's diphtheria-pertussis-tetanus-based combination vaccines from its register of prequalified products.